PDF
File
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Vård & Omsorg |
BRAIN+ A/S (BRAINP)
Company Announcement No. [1-2022]
[Thursday January 27, 2022, 17:00 CET]
Bertil S. Jessen will join Brain+ as the company's Chief Financial Officer ("CFO") on March 1, 2022. Bertil will add further key competences to the leadership team as he brings solid international business and corporate finance as well as strategic partnership experience. He joins Brain+ from a position as head of a global strategic business program in GN Store Nord and has previous experience from strategy and M&A advisory roles in Maersk and in J.P. Morgan's investment banking division.
Kim Baden-Kristensen, CEO "I am thrilled to welcome Bertil to Brain+ as our CFO. Our company has evolved to the point where we need a designated CFO to take on the full responsibility for our financial planning and reporting, our capital management and investor relations efforts. Successful execution in these areas are integral to the continued progression of our pipeline, and Bertil brings a unique set of capabilities to the role. With Bertil on board we now have top talent across all functional areas."
Incoming CFO Bertil Jessen "Brain+ is one of those rare gems - a collection of highly talented people with groundbreaking ideas, completely undeterred in taking on one of society's greatest public health challenges. I feel nothing short of privileged to have the opportunity to help our stakeholders on this journey to detect and develop new Alzheimer's and dementia treatments."
Contact Information
The Company:
CEO, Kim Baden-Kristensen + 45 31393318
E-mail: kim@brain-plus.com
Brain+ A/S
Købmagergade 53, 3.
Certified Advisor:
Keswick Global AG
+ 43 1 740 408045
E-mail: info@keswickglobal.com
About BRAIN+ [BRAINP]
The mission of Brain+ is to restore patients' independence and quality of life by treating and detecting cognitive decline in Alzheimer's disease and dementia through software-as-medicine applications. Brain+ has developed a set of software-as-medicine technologies, which enable the Company to create a unique and differentiated product offering. These technologies, combined with a strong clinical pipeline, puts Brain+ in a strong position to grow towards a market leader position in the Digital Therapeutics (DTx) space.